These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9854508)

  • 1. Clinical experience of EET therapy for 75 advanced cancer patients.
    Kato M; Shinohara H; Goto S; Takagi K; Soma G
    Anticancer Res; 1998; 18(5D):3941-9. PubMed ID: 9854508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous TNF induction therapy using rTNF-SAM2 in patients with pulmonary metastases from colorectal cancer.
    Yamasaki K; Hasegawa S; Futami K; Arima S
    Anticancer Res; 1998; 18(5D):3931-6. PubMed ID: 9854506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients.
    Tomita A; Fuchino Y; Otsuka K; Shinohara T; Tanaka SN; Umeno T; Ikeda S
    Anticancer Res; 1998; 18(5D):3937-9. PubMed ID: 9854507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2) immunotherapy with ranimustine chemotherapy and concurrent radiation therapy for malignant astrocytomas.
    Fukushima T; Yamamoto M; Oshiro S; Tsugu H; Hirakawa K; Soma G
    Anticancer Res; 2003; 23(6a):4473-81. PubMed ID: 14666736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF.
    Inagawa H; Oshima H; Soma G; Mizuno D
    J Biol Response Mod; 1988 Dec; 7(6):596-607. PubMed ID: 3216223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironment.
    Yamaguchi Y; Ohshita A; Kawabuchi Y; Hihara J; Miyahara E; Noma K; Toge T
    Int J Oncol; 2004 Apr; 24(4):959-66. PubMed ID: 15010836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
    Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer.
    Nakamori M; Iwahashi M; Nakamura M; Ueda K; Zhang X; Yamaue H
    Clin Cancer Res; 2003 Jun; 9(6):2357-65. PubMed ID: 12796406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor, cancer and anticancer therapy.
    Mocellin S; Rossi CR; Pilati P; Nitti D
    Cytokine Growth Factor Rev; 2005 Feb; 16(1):35-53. PubMed ID: 15733831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The metastatic tumor and immunotherapy].
    Fuchimoto S; Orita K
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1260-5. PubMed ID: 2730024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2).
    Yamamoto M; Fukushima T; Hayashi S; Ikeda K; Tsugu H; Kimura H; Soma G; Tomonaga M
    Anticancer Res; 2000; 20(1C):611-8. PubMed ID: 10769704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-alpha and novel strategies of combination therapy for cancer.
    Bracci L; Proietti E; Belardelli F
    Ann N Y Acad Sci; 2007 Sep; 1112():256-68. PubMed ID: 17567945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
    Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
    Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
    Schlienger K; Chu CS; Woo EY; Rivers PM; Toll AJ; Hudson B; Maus MV; Riley JL; Choi Y; Coukos G; Kaiser LR; Rubin SC; Levine BL; Carroll RG; June CH
    Clin Cancer Res; 2003 Apr; 9(4):1517-27. PubMed ID: 12684428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.